# Illumina, Inc. – Consensus ‘hold’ rating and 62.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/illumina-inc.consensus-hold-rating-and-62.8-upside-potential/4121132302
- Published: 2023-11-09T13:15:33+00:00
- Author: Charlotte Edwards

**Illumina, Inc.** which can be found using ticker (ILMN) have now 18 market analysts
covering the stock. The analyst consensus now points to a rating of ‘hold’. The 
range between the high target price and low target price is between $318.00 and 
$100.00 with the average target price sitting at $186.44. Now with the previous 
closing price of $114.50 and the analysts are correct then there would likely be
a percentage uptick in value of 62.8%. It’s also worth noting that there is a 50
day moving average of $133.81 and the 200 day MA is $184.96. The market cap for 
the company is 17.52B. The stock price for the company is currently $110.70 USD

 The potential market cap would be $28,533,966,752 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $28.32 and
a -0.79% return on assets.

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic
and genomic analysis. The Company operates through two segments: Core Illumina and
GRAIL. Its Core Illumina segment offers products and services that serve customers
in the research, clinical and applied markets, and enable the adoption of a variety
of genomic solutions. Its GRAIL segment is a healthcare company focused on early
detection of multiple cancers. Its portfolio of integrated sequencing and microarray
systems, consumables, and analysis tools is designed to accelerate and simplify 
genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing
instruments, allowing customers to manage their biological sample and sequencing
runs, process and analyze the raw genomic data, and derive results. Its BeadArray
technology combines microscopic beads and a substrate in a proprietary manufacturing
process to produce arrays that can perform various assays simultaneously.

Share on: